VSPPLTLGQLLS (TFA)

VSPPLTLGQLLS TFA is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation[1][2].

Product Specifications

UNSPSC

12352209

Target

FGFR

Type

Peptides

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vsppltlgqlls-tfa.html

Solubility

10 mM in DMSO

Smiles

OC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@H](CC(C)C)NC([C@H]1N(C([C@H]2N(C([C@H](CO)NC([C@H](C(C)C)N)=O)=O)CCC2)=O)CCC1)=O)=O)=O)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F

Molecular Formula

C58H98F3N13O19

Molecular Weight

1338.47

References & Citations

[1]Perrault DP, et al. Small Peptide Modulation of Fibroblast Growth Factor Receptor 3-Dependent Postnatal Lymphangiogenesis. Lymphat Res Biol. 2019 Feb;17 (1) :19-29. |[2]Jin M, et al. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum Mol Genet. 2012 Dec 15;21 (26) :5443-55.